A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer

Advanced Non-small Cell Lung Cancer Clinical Trial

Official title:

Phase IB/II Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer With HER2

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05482568
• Other study ID #: SHR-A1811-II-203
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: September 15, 2022
• Est. completion date: December 30, 2024

Study information

• Verified date: October 2023
• Source: Jiangsu HengRui Medicine Co., Ltd.
• Contact: Suqiang Yu
• Phone: +0518-82342973
• Email: suqiang.yu[@]hengrui.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study was an open, multicenter, dose-increasing/investigational Phase IB/II clinical trial to evaluate the efficacy of SHR-A1811 in combination with other antitumor therapies in subjects with advanced non-small cell lung cancer with HER2 . It can be divided into two parts, Part A is the dose escalation and efficacy exploration study of SHR-A1811 combined with Pyrotinib, and Part B is the dose escalation and efficacy exploration study of SHR-A1811 combined with SHR-1316.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 324
• Est. completion date: December 30, 2024
• Est. primary completion date: November 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Ability to give informed consent, signed and dated IRB/EC approved informed consent, willing and able to comply with treatment planning visits, tests and other procedural requirements

2. When signing the informed consent, the age is 18-75 years old (including both ends), and there is no gender limitation

3. The ECOG score is 0 or 1

4. The expected survival is =12 weeks

5. Subjects with advanced or metastatic non-small cell lung cancer

6. Formalin fixed, paraffin-embedded tumor tissue blocks or sections of unstained tumor specimens are provided

7. Subjects who have failed prior standard care or are intolerant to standard care

8. There is at least one measurable lesion

9. Vital organs are functioning well

10. Heart function is good

11. Agree to birth control

Exclusion Criteria:

1. There are untreated or active central nervous system (CNS) tumor metastases

2. Pleural, ascites, or pericardial effusion requiring intervention occurred within 7 days prior to initial administration

3. Systemic antitumor therapy was performed 4 weeks prior to study initiation

4. Prior treatment with antibody-conjugated drugs

5. Received >30 Gy chest radiation within 6 months prior to initial administration

6. Palliative radiotherapy was completed within 7 days prior to initial administration

7. Failure to recover from toxicity and/or complications of previous interventions to nCI-CTCAE =1

8. The half-life of CYP3A4 suppressor, moderate inhibitor or strong inducer or moderate inducer is less than 3 or less than 14 days from the date of first drug use, and the shorter is selected

9. Received systemic immunosuppressant therapy within 14 days prior to the first study

10. Subjects with known or suspected interstitial pneumonia

11. In the first study, failure to swallow, chronic diarrhea, gastroenteritis, intestinal obstruction, gastrointestinal perforation, postgastrectomy, or colitis, or other medical conditions or special conditions affecting drug administration and absorption occurred within 28 days prior to administration

12. Presence of any active, known or suspected autoimmune disease

13. Have poorly controlled or severe cardiovascular disease

14. Previous or concurrent malignancy

15. Subjects who developed a severe infection within 28 days prior to the first dose

16. Active hepatitis B

17. There were active tuberculosis patients within 1 year before enrollment

18. There is a history of immunodeficiency

19. Live attenuated vaccine was administered within 28 days prior to initial study administration or is expected to be administered during study treatment

20. Subjects who are participating in another clinical study or who have had their first dose less than 4 weeks since the end of the previous clinical study (last dose) or 5 half-lives of the study drug, whichever is shorter

21. Major surgery other than diagnosis or biopsy was performed within 28 days prior to initial administration

22. People who are known to be allergic to sir-A1811, pyrrolitinib, or any of the components of SIR-1316

23. History of severe allergic reactions to other monoclonal antibody/fusion protein drugs

24. Female subjects who are pregnant, breast-feeding, or planning to become pregnant during the study

25. Uncontrolled mental illness and other conditions known to affect the completion of the study process, such as alcohol, drug or substance abuse and detention

26. Any other conditions that, in the investigator's judgment, may increase the risk of study participation, interfere with study results, or make study participation unsuitable

Related Conditions & MeSH terms

• Advanced Non-small Cell Lung Cancer
• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms

Intervention

Drug:
• SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316
Drug: SHR-A1811 & Pyrotinib SHR-A1811: intravenous Pyrotinib:oral Drug: SHR-A1811 & SHR-1316 SHR-A1811: intravenous SHR-1316: intravenous

Locations

Country	Name	City	State
China	Zhejiang Cancer Hospital	Hangzhou	Zhejiang
China	Shanghai Chest hospital	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Jiangsu HengRui Medicine Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	DLT(Phase I (dose exploration phase) main study endpoint)		21 days after the first administration of each subject
Primary	AE(Phase I (dose exploration phase) main study endpoint)		Two years after the last subject was enrolled in the group
Primary	Incidence and severity of serious adverse events (SAE)(Phase I (dose exploration phase) main study endpoint)		Two years after the last subject was enrolled in the group
Primary	Objective response rate(The main end points of the second stage (efficacy expansion stage))		Two years after the last subject was enrolled in the group
Secondary	Toxin binding antibody to shr-a1811(Phase I secondary endpoint)		Two years after the last subject was enrolled in the group
Secondary	Total antibody to shr-a1811(Phase I secondary endpoint)		Two years after the last subject was enrolled in the group
Secondary	Plasma concentration of free toxin shr169265(Phase I secondary endpoint)		Two years after the last subject was enrolled in the group
Secondary	Plasma concentration of pyrroltinib(Phase I secondary endpoint)		Two years after the last subject was enrolled in the group
Secondary	Plasma concentration of SHR-1316(Phase I secondary endpoint)		Two years after the last subject was enrolled in the group
Secondary	Anti shr-a1811 antibody positive(Phase I secondary endpoint)		Two years after the last subject was enrolled in the group
Secondary	The positive status of neutralizing antibody against shr-a1811(Phase I secondary endpoint)		Two years after the last subject was enrolled in the group
Secondary	Anti shr-1316 antibody positive(Phase I secondary endpoint)		Two years after the last subject was enrolled in the group
Secondary	The positive status of neutralizing antibody against shr-1316(Phase I secondary endpoint)		Two years after the last subject was enrolled in the group
Secondary	Objective Response Rate(Phase I secondary endpoint)		Two years after the last subject was enrolled in the group
Secondary	Duration of response(Phase I secondary endpoint)		Two years after the last subject was enrolled in the group
Secondary	Progression Free Survival(Phase I secondary endpoint)		Two years after the last subject was enrolled in the group
Secondary	AE(Phase II secondary study endpoint)		Two years after the last subject was enrolled in the group
Secondary	Incidence and severity of serious adverse events (SAE)(Phase II secondary study endpoint)		Two years after the last subject was enrolled in the group
Secondary	Toxin binding antibody to shr-a1811(Phase II secondary study endpoint)		Two years after the last subject was enrolled in the group
Secondary	Total antibody to shr-a1811(Phase II secondary study endpoint)		Two years after the last subject was enrolled in the group
Secondary	Plasma concentration of free toxin shr169265(Phase II secondary study endpoint)		Two years after the last subject was enrolled in the group
Secondary	Plasma concentration of pyrroltinib(Phase II secondary study endpoint)		Two years after the last subject was enrolled in the group
Secondary	Plasma concentration of SHR-1316(Phase II secondary study endpoint)		Two years after the last subject was enrolled in the group
Secondary	Anti shr-a1811 antibody positive(Phase II secondary study endpoint)		Two years after the last subject was enrolled in the group
Secondary	The positive status of neutralizing antibody against shr-a1811(Phase II secondary study endpoint)		Two years after the last subject was enrolled in the group
Secondary	Anti shr-1316 antibody positive(Phase II secondary study endpoint)		Two years after the last subject was enrolled in the group
Secondary	The positive status of neutralizing antibody against shr-1316(Phase II secondary study endpoint)		Two years after the last subject was enrolled in the group
Secondary	Duration of response(Phase II secondary study endpoint)		Two years after the last subject was enrolled in the group
Secondary	Progression Free Survival(Phase II secondary study endpoint)		Two years after the last subject was enrolled in the group